Alkermes Q3 2024 Financial Results

Alkermes Plc (NASDAQ:ALKS) has reported strong financial performance in Q3 2024, with total revenues of $378.1 million, up 18% year-over-year. This growth was primarily due to the successful proprietary products, including VIVITROL, ARISTADA, and LYBALVI. Looking ahead to 2025, Alkermes aims to focus on significant cash flow and profitability while advancing its clinical program, ALKS 2680, for narcolepsy.

Despite expecting a decline in EBITDA from about $400 million to over $200 million because of manufacturing transitions and royalty revenue changes, the company maintains an optimistic growth outlook, especially in bipolar and schizophrenia markets.

Key Takeaways

• Revenues reached $378.1 million, an 18% increase from the previous year.
• Key product sales included: VIVITROL: $113.7 million, ARISTADA: $84.7 million, LYBALVI: $74.7 million.
• GAAP net income was $92.8 million, with cash totaling $927.8 million.
• Alkermes plans to focus on proprietary products and anticipates an EBITDA of over $200 million in 2025.
• Ongoing Phase 2 studies for ALKS 2680.

Company Outlook

• Anticipated net sales for VIVITROL: $410-$430 million; LYBALVI: $275-$295 million; ARISTADA: $340-$360 million.
• Expected $200 million decline in royalty and manufacturing revenues in 2025 due to the cessation of royalties from INVEGA SUSTENNA.
• Strategic focus on enhancing shareholder value through profitability.

Performance Highlights

• Anticipated EBITDA decline attributed to both manufacturing transitions and increased R&D for LYBALVI and ARISTADA.
• Advancements in the ALKS 2680 clinical program are critical as Phase 2 studies continue.
• The company monitors competitive pressures but remains optimistic about its market position and pipeline.

Q&A Summary

Umer Raffat asked about the reasons for expected EBITDA decline, which is largely due to royalty revenue impacts. Management indicated a modest increase in SG&A expenses related to R&D investments. There were no significant misses in operational targets during the quarter, and the Q&A indicated that Alkermes remains on track for its financial expectations.